What is the 13F Pro Quality Score for IONS?

13F Pro ranks IONIS PHARMACEUTICALS INC (IONS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IONS's current score at https://13fpro.ai/company/IONS (free sign-up required for the full ranking).

Which hedge funds own the most IONS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IONS include FMR, Capital World Investors, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/IONS as soon as new 13F filings post.

Where does 13F Pro source IONS data?

All IONIS PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. IONIS PHARMACEUTICALS INC files with the SEC under CIK 874015. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IONS in?

IONIS PHARMACEUTICALS INC (IONS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IONS research updated on 13F Pro?

IONS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IONIS PHARMACEUTICALS INC(IONS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 874015 IONS stock profile & AI dashboard →

13F Pro Quality Score

23.4/100

Rank #2,720 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

37.3/100

Profitability

9.0/100

Balance Sheet

11.6/100

Earnings Quality

14.9/100

Free Cash Flow

8.2/100

Institutional Flow

46.8/100

Revenue Scale

47.9/100

Dilution Risk

12.3/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IONS Scores 23/100

exact factor attribution · 2026-09-11

IONS's composite is held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-0.2 pts

47th pct

Scale

-0.3 pts

48th pct

Shareholder dilution

-1.9 pts

12th pct

Earnings growth

-1.9 pts

11th pct

Revenue growth

-2.5 pts

37th pct

Earnings quality

-3.5 pts

15th pct

Capital efficiency

-3.8 pts

12th pct

Profitability

-6.2 pts

9th pct

Free cash flow

-6.3 pts

8th pct

Latest change (2026-07-29): 37 → 25 · ↓ Revenue growth 88→38; ↓ Capital efficiency 21→13

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in IONS

Events flagged as statistical outliers against IONS's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-07-29
IONS quality score dropped 12 points (37→25) on a new filing
View source filing →

IONS Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for IONIS PHARMACEUTICALS INC (IONS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IONS at 23.4/100 on a 32-signal composite quality model, placing it at rank #2,720 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (8.2) and profitability (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IONIS PHARMACEUTICALS INC reports quarterly revenue of $267.9M, net income of $-114.6M, an operating margin of -38.2%. Top institutional holders of IONS by reported 13-F value include FMR, Capital World Investors, BlackRock, based on the most recent SEC filings. IONS trades on the Nasdaq exchange and files with the SEC under CIK 874015. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IONS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IONIS PHARMACEUTICALS INC directly from SEC EDGAR. IONIS PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 20 and 37 since 2021, currently 23.4 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$267.9M

Net Income

Q2 2026

$-114.6M

Free Cash Flow

Q2 2026

$549.5M

Operating Margin

Q2 2026

-38.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+33.8% YoY

$943.7MFY 2025

FY22 $587.4MFY23 $787.6MFY24 $705.1MFY25 $943.7M

Net Income

+16.0% YoY

$-381.4MFY 2025

FY22 $-269.7MFY23 $-366.3MFY24 $-453.9MFY25 $-381.4M

Operating Income

+19.7% YoY

$-381.7MFY 2025

FY22 $-410.2MFY23 $-353.7MFY24 $-475.1MFY25 $-381.7M

EPS (Diluted)

+21.7% YoY

$-2.38FY 2025

FY22 $-1.90FY23 $-2.56FY24 $-3.04FY25 $-2.38

Total Assets

+17.3% YoY

$3.52BFY 2025

FY22 $2.53BFY23 $2.99BFY24 $3.00BFY25 $3.52B

Total Debt

+79.1% YoY

$2.24BFY 2025

FY22 $1.19BFY23 $1.31BFY24 $1.25BFY25 $2.24B

Op. Cash Flow

+46.4% YoY

$-268.6MFY 2025

FY22 $-274.4MFY23 $-307.5MFY24 $-500.9MFY25 $-268.6M

Free Cash Flow

+41.4% YoY

$-320.0MFY 2025

FY22 $-290.1MFY23 $-331.3MFY24 $-546.2MFY25 $-320.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$943.7M +33.8%	$705.1M -10.5%	$787.6M +34.1%	$587.4M -27.5%	$810.5M +11.1%	$729.3M
Net Income	$-381.4M +16.0%	$-453.9M -23.9%	$-366.3M -35.8%	$-269.7M -843.2%	$-28.6M +93.6%	$-444.3M
Operating Income	$-381.7M +19.7%	$-475.1M -34.3%	$-353.7M +13.8%	$-410.2M -1258.9%	$-30.2M +82.5%	$-172.1M
EPS (Diluted)	$-2.38 +21.7%	$-3.04 -18.8%	$-2.56 -34.7%	$-1.90 -850.0%	$-0.20 +93.7%	$-3.18
Total Assets	$3.52B +17.3%	$3.00B +0.5%	$2.99B +18.0%	$2.53B -3.0%	$2.61B +9.3%	$2.39B
Total Debt	$2.24B +79.1%	$1.25B -4.2%	$1.31B +9.6%	$1.19B	—	$839.6M
Operating Cash Flow	$-268.6M +46.4%	$-500.9M -62.9%	$-307.5M -12.1%	$-274.4M -990.8%	$30.8M -14.2%	$35.9M
Free Cash Flow	$-320.0M +41.4%	$-546.2M -64.9%	$-331.3M -14.2%	$-290.1M -1639.4%	$18.8M +2340.9%	$772.0K

Get alerted when IONS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IONIS PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IONS

FMR LLC
$2.0B24,631,956 sh
Capital World Investors
$1.7B21,669,226 sh
BlackRock, Inc.
$848.8M10,704,660 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$623.2M7,859,529 sh
WELLINGTON MANAGEMENT GROUP LLP
$606.7M7,651,415 sh
VANGUARD CAPITAL MANAGEMENT LLC
$571.8M7,211,497 sh
TWO SIGMA INVESTMENTS, LP
$495.7M6,252,342 sh
ROYAL BANK OF CANADA
$490.2M6,182,479 sh
STATE STREET CORP
$343.7M4,334,848 sh
T. Rowe Price Investment Management, Inc.
$313.9M3,959,372 sh

Fund	Value	Shares
FMR LLC	$2.0B	24,631,956
Capital World Investors	$1.7B	21,669,226
BlackRock, Inc.	$848.8M	10,704,660
VANGUARD PORTFOLIO MANAGEMENT LLC	$623.2M	7,859,529
WELLINGTON MANAGEMENT GROUP LLP	$606.7M	7,651,415
VANGUARD CAPITAL MANAGEMENT LLC	$571.8M	7,211,497
TWO SIGMA INVESTMENTS, LP	$495.7M	6,252,342
ROYAL BANK OF CANADA	$490.2M	6,182,479
STATE STREET CORP	$343.7M	4,334,848
T. Rowe Price Investment Management, Inc.	$313.9M	3,959,372

Companies Similar to IONS

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 31 shared holders

Polar Capital Holdings Plc Bellevue Group AG SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC

Guardant Health, Inc.

AI score

Similar quality profile · 32 shared holders

Artisan Partners Limited Partnership Deep Track Capital, LP Alyeska Investment Group, L.P.

RARE

Ultragenyx Pharmaceutical Inc.

AI score

Similar quality profile · 23 shared holders

Bellevue Group AG VOLORIDGE INVESTMENT MANAGEMENT, LLC Candriam S.C.A.

INSM

INSMED Inc

AI score

Similar quality profile · 31 shared holders

Artisan Partners Limited Partnership T. Rowe Price Investment Management, Inc.BAKER BROS. ADVISORS LP

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Similar quality profile · 25 shared holders

Capital World Investors Polar Capital Holdings Plc TENOR CAPITAL MANAGEMENT Co., L.P.

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

AI score

Similar quality profile · 32 shared holders

BAKER BROS. ADVISORS LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC

IDYA

IDEAYA Biosciences, Inc.

AI score

Similar quality profile · 20 shared holders

BAKER BROS. ADVISORS LP DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)Candriam S.C.A.

PTCT

PTC THERAPEUTICS, INC.

AI score

Similar quality profile · 12 shared holders

LORD, ABBETT & CO. LLC SECTOR GAMMA AS PINNACLE ASSOCIATES LTD

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IONS on your watchlist

Track score changes the day IONIS PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IONS a good stock to buy?

13F Pro's AI-powered analysis of IONIS PHARMACEUTICALS INC (IONS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IONS are available on the IONS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IONS is classified as a mid company.

Which hedge funds own IONS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IONS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IONIS PHARMACEUTICALS INC's investment landscape.